Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Stock Information for Hemostemix

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hemostemix

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Hemostemix Clarifies its October 3, 2023 News Release
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Hemostemix Closed $320,125 Private Placement
Hemostemix Announces Private Placement
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.